J&J's Ethicon Calls For Game-Changing Holistic Approach To Obesity Care
At this year's 22nd World Congress of the International Federation for the Surgery of Obesity and Metabolic Diseases, Johnson & Johnson subsidiary Ethicon launched a new initiative to significantly alter the way obesity is viewed and to change the patient care pathway for the better.
You may also be interested in...
Animas, a division of Johnson & Johnson, will stop making Animas Vibe and OneTouch Ping insulin pumps, close operations, and exit the insulin pump business, the company announced Oct. 5. J&J is offering patients currently using these devices the option to transfer to Medtronic device. Medtronic is already the leading supplier of insulin pumps worldwide.
The Dutch company received the US FDA's breakthrough device designation in 2018 for the surgical patch.
Johnson & Johnson previously agreed to acquire TachoSil but terminated the transaction due to regulatory hurdles.